NEW HAVEN, Conn., November 2, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that it has appointed Paula Soteropoulos to its Board of Directors. Ms. Soteropoulos is an accomplished biopharmaceutical industry leader with more than 30 years of rare disease experience in strategic and operational leadership areas including drug development, global commercialization, manufacturing, new company formation and company building.
“Paula’s rare disease-focused leadership roles at global pharmaceutical and biotechnology companies will add significant value as we continue to advance our current pipeline and further expand our portfolio,” said Rallybio co-founder, Dr. Martin Mackay. “We look forward to leveraging her valuable commercial expertise and insights, and are pleased to welcome her innovative perspectives and industry knowledge to Rallybio’s Board of Directors.”
“I am pleased to join Rallybio’s Board of Directors and look forward to collaborating with the outstanding team and other respected Board members to bring my background and experiences to support Rallybio’s mission,” said Ms. Soteropoulos. “I look forward to contributing to the future success of Rallybio and improving the lives of patients in need through its portfolio of potentially life-transforming product candidates.”
Ms. Soteropoulos’ leadership throughout her career spans a broad range of therapeutic areas. In addition to her strong focus in rare disease, her expertise includes cardiovascular and metabolism, neurology, infectious disease, renal, and transplant and oncology. She currently serves as Executive Chairman of a venture-backed biotechnology company and a member of the Board of Directors of uniQure. Previously, she served as founding CEO and member of the Board of Directors of Akcea Therapeutics, a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases.
Prior to Akcea, she was Senior Vice President and General Manager of Cardiometabolic and Rare Disease Businesses and Strategic Alliances at Moderna, Inc. where she led key strategic alliances and built preclinical programs and alliances. Before Moderna, Ms. Soteropoulos spent more than 20 years at Genzyme Corporation where she held positions of increasing responsibility including Vice President and General Manager, Cardiovascular, Rare Diseases. In this role, Ms. Soteropoulos led all aspects of the cardiovascular business from early portfolio prioritization of science and new business development opportunities through commercialization.
Ms. Soteropoulos earned an executive management certificate from the University of Virginia – Darden Graduate School of Business Administration, and a Master of Science in Chemical and Biochemical Engineering and a Bachelor of Science in Chemical Engineering from Tufts University.
Rallybio is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, and metabolism. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.